Spyre Therapeutics Inc. (SYRE) - Net Assets
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has net assets worth $1.10 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.17 Billion) and total liabilities ($71.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See how leveraged is Spyre Therapeutics Inc.'s balance sheet to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.10 Billion |
| % of Total Assets | 93.87% |
| Annual Growth Rate | 57.02% |
| 5-Year Change | 752.07% |
| 10-Year Change | 1035.91% |
| Growth Volatility | 499.79 |
Spyre Therapeutics Inc. - Net Assets Trend (2013–2025)
This chart illustrates how Spyre Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Spyre Therapeutics Inc. (SYRE) total market value.
Annual Net Assets for Spyre Therapeutics Inc. (2013–2025)
The table below shows the annual net assets of Spyre Therapeutics Inc. from 2013 to 2025. Also explore Spyre Therapeutics Inc. equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $715.24 Million | +38.13% |
| 2024-12-31 | $517.80 Million | +181.39% |
| 2023-12-31 | $184.02 Million | +265.80% |
| 2022-12-31 | $50.30 Million | -40.07% |
| 2021-12-31 | $83.94 Million | -39.97% |
| 2020-12-31 | $139.83 Million | +132.74% |
| 2019-12-31 | $60.08 Million | -10.90% |
| 2018-12-31 | $67.43 Million | +33.95% |
| 2017-12-31 | $50.34 Million | -20.06% |
| 2016-12-31 | $62.97 Million | +74.40% |
| 2015-12-31 | $36.10 Million | +1828.63% |
| 2014-12-31 | $1.87 Million | -41.22% |
| 2013-12-31 | $3.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Spyre Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 112569800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00K | 0.00% |
| Other Comprehensive Income | $869.00K | 0.12% |
| Other Components | $1.84 Billion | 257.54% |
| Total Equity | $715.24 Million | 100.00% |
Spyre Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Spyre Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Suzhou Maxwell Technologies Co Ltd Class A
SHE:300751
|
$8.04 Billion |
|
BOK Financial Corporation
NASDAQ:BOKF
|
$8.05 Billion |
|
Hindustan Petroleum Corporation Limited
NSE:HINDPETRO
|
$8.06 Billion |
|
Viavi Solutions Inc
NASDAQ:VIAV
|
$8.06 Billion |
|
Sichuan Em Technology Co Ltd
SHG:601208
|
$8.03 Billion |
|
NEMETSCHEK UNSP.ADR/02
F:NEM0
|
$8.03 Billion |
|
Wallenius Wilhelmsen Logistics ASA
OL:WAWI
|
$8.02 Billion |
|
Stantec Inc
TO:STN
|
$8.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Spyre Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 517,804,000 to 715,236,000, a change of 197,432,000 (38.1%).
- Net loss of 155,203,000 reduced equity.
- New share issuances of 311,132,000 increased equity.
- Other comprehensive income increased equity by 689,000.
- Other factors increased equity by 40,814,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-155.20 Million | -21.7% |
| Share Issuances | $311.13 Million | +43.5% |
| Other Comprehensive Income | $689.00K | +0.1% |
| Other Changes | $40.81 Million | +5.71% |
| Total Change | $- | 38.13% |
Book Value vs Market Value Analysis
This analysis compares Spyre Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 26.65x to 8.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $3.42 | $91.17 | x |
| 2015-12-31 | $78.97 | $91.17 | x |
| 2016-12-31 | $160.76 | $91.17 | x |
| 2017-12-31 | $83.18 | $91.17 | x |
| 2018-12-31 | $80.96 | $91.17 | x |
| 2019-12-31 | $47.01 | $91.17 | x |
| 2020-12-31 | $65.50 | $91.17 | x |
| 2021-12-31 | $31.92 | $91.17 | x |
| 2022-12-31 | $14.92 | $91.17 | x |
| 2023-12-31 | $26.68 | $91.17 | x |
| 2024-12-31 | $11.01 | $91.17 | x |
| 2025-12-31 | $11.17 | $91.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Spyre Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-21.70%) is above the historical average (-118.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -552.72% | 0.00% | 0.00x | 1.57x | $-10.53 Million |
| 2015 | -31.28% | -185.62% | 0.16x | 1.07x | $-14.91 Million |
| 2016 | -34.46% | -468.84% | 0.07x | 1.07x | $-27.99 Million |
| 2017 | -54.11% | -523.27% | 0.09x | 1.11x | $-32.27 Million |
| 2018 | -65.77% | -1140.64% | 0.05x | 1.15x | $-51.09 Million |
| 2019 | -130.25% | 0.00% | 0.00x | 1.38x | $-84.26 Million |
| 2020 | -57.85% | 0.00% | 0.00x | 1.16x | $-94.88 Million |
| 2021 | -78.39% | -351.14% | 0.17x | 1.31x | $-74.20 Million |
| 2022 | -166.61% | -3598.75% | 0.03x | 1.41x | $-88.85 Million |
| 2023 | -184.11% | -38238.15% | 0.00x | 1.86x | $-357.19 Million |
| 2024 | -40.17% | -23478.33% | 0.00x | 1.18x | $-259.80 Million |
| 2025 | -21.70% | 0.00% | 0.00x | 1.09x | $-226.73 Million |
Industry Comparison
This section compares Spyre Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $201,571,196
- Average return on equity (ROE) among peers: -90.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Spyre Therapeutics Inc. (SYRE) | $1.10 Billion | -552.72% | 0.07x | $8.04 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $112.13 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $44.03 Million | -144.75% | 1.47x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.36 Billion |
| Arbutus Biopharma Corp (ABUS) | $76.58 Million | -43.75% | 0.24x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $723.96K | -677.23% | 9.41x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $8.92 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $732.79 Million | 30.90% | 0.62x | $4.75 Billion |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more